Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Better Biotech Buy: Alexion Pharmaceuticals, Inc. vs. Regeneron

By Dan Carroll - Mar 12, 2014 at 2:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two big biotech stocks have captured investor attention for their impressive growth over the past year, but is Alexion or Regeneron more likely to keep up the momentum in the future?

Big biotech stocks like Alexion Pharmaceuticals ( ALXN ) and Regeneron ( REGN 0.17% ) have soared through the market's recent rally with flying colors. These two stocks alone each have captured more than 90% growth over that time, as climbing sales of top drugs have impressed investors and Wall Street. Regeneron and Alexion look like winners heading forward, but which company -- and stock -- is on the best track for long-term growth?

Alexion's grown famous for Soliris, its orphan drug that's the most expensive in the world. Soliris isn't just a pricey therapy, however; it's also an unstoppable blockbuster, reaping more than $1.5 billion in sales last year at growth of 37% year over year. Analysts think Alexion's top drug has plenty more room to run, but big biotech peer Regeneron has a star drug of its own. Regeneron'seye therapy Eylea has taken the biotech world by storm over the past year, reaping more than $1.8 billion in global sales last year and on pace to pick up more revenue this year.

Both companies have developing programs in their pipelines as well, but which stock is more worthy of your investment? Find out in the video below, as Motley Fool contributor Dan Carroll takes you through the ins and outs of these two soaring stocks and their standout drugs -- and which one's set up for the best growth in the future.

)
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$637.63 (0.17%) $1.10
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN
Sanofi Stock Quote
Sanofi
SNY
$48.35 (1.64%) $0.78
IVERIC bio, Inc. Stock Quote
IVERIC bio, Inc.
ISEE
$14.40 (-1.47%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.